Characterization of MK-801-induced behavior as a putative rat model of psychosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1393-1408

  Andiné, Peter ^a,b   Widermark, Nina ^b   Axelsson, Rolf ^a   Nyberg, Gösta ^a   Olofsson, Ulla ^a   Mårtensson, Erik ^a   Sandberg, Mats ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG POTENCY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SEX DIFFERENCE;

AGING; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GABA ANTAGONISTS; ISOXAZOLES; MALE; MOTOR ACTIVITY; PSYCHOSES, SUBSTANCE-INDUCED; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA; SEX CHARACTERISTICS; STEREOTYPED BEHAVIOR; STEREOTYPIC MOVEMENT DISORDER;

EID: 0032797438     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Albers GW, Atkinson RP, Kelley RE and Rosenbaum DM (1995) Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26:254-258.
2. Becker JB, Robinson TE and Lorenz KA (1982) Sex differences and estrous cycle variations in amphetamine-elicited rotational behavior. Eur J Pharmacol 80:65-72.
3. Bresink I, Danysz W, Parsons CG and Mutschler E (1995) Different binding affinities of NMDA receptor channel blockers in various brain regions-Indication of NMDA receptor heterogeneity. Neuropharmacology 34:533-540.
4. Bristow LJ, Hutson PH, Thorn L and Tricklebank MD (1993) The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br J Pharmacol 108:1156-1163.
5. Browne RG and Welch WM (1982) Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. Science (Wash DC) 217: 1157-1159.
6. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186.
7. Carlsson M and Carlsson A (1989) Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine. J Neural Transm Park Dis Dement Sect 1:317-322.
8. Carlsson M and Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-Implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
9. Carlsson ML (1993) Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? (Hypothesis). J Neural Transm Gen Sect 94:1-10.
10. Carlsson ML, Engberg G and Carlsson A (1994) Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice. J Neural Transm Gen Sect 95:223-233.
11. Cascella NG, Macciardi F, Cavallini C and Smeraldi E (1994) D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J Neural Transm Gen Sect 95:105-111.
12. Castro CA, Hogan JB, Benson KA, Shehata CW and Landauer MR (1995) Behavioral effects of vehicles: DMSO, ethanol, Tween-20, Tween-80 and emulphor-620. Pharmacol Biochem Behav 50:521-526.
13. Contreras PC (1990) D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology 29:291-293.
14. Criswell HE, Johnson KB, Mueller RA and Breese GR (1993) Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J Pharmacol Exp Ther 265:1001-1010.
15. Danysz W, Essmann U, Bresink I and Wilke R (1994) Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48:111-118.
16. Davies SN, Martin D, Millar JD, Aram JA, Church J and Lodge D (1988) Difference in results from in vivo and in vitro studies on the use-dependency of N-methylaspartate antagonism by MK-801 and other phencyclidine receptor ligands. Eur J Pharmacol 145:141-151.
17. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB and Morihisa JM (1989) A "glutamatergic" hypothesis of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12:1-13.
18. 2-mediated behaviour in short-term reserpinized mice. Eur J Pharmacol 192:25-30.
19. Fredholm BB and Dunwiddie TV (1988) How does adenosine inhibit transmitter release? Trends Pharmacol Sci 9:130-134.
20. Freed WJ, Bing LA and Wyatt RJ (1984) Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropharmacology 23:175-181.
21. 2 receptor interactions in the striatum as a basis for adenosine/ dopamine interactions in the central nervous system. Drug Dev Res 28:374-380.
22. Ginski MJ and Witkin JM (1994) Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology 114:573-582.
23. 3H]DOPA in various regions of the brain. J Neurochem 13:655-669.
24. Goff DC, Tsai G, Manoach DS and Coyle JS (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
25. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D and LaRue L (1995) Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Stroke 26:602-605.
26. Heffner TG, Wiley JN, Williams AE, Bruns RF, Coughenour LL and Downs DA (1989) Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 98:31-37.
27. Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 89:1-10.
28. Hucker HB, Hutt JE, White SD, Arison BH and Zacchei AG (1983) Disposition and metabolism of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-5,10-imine in rats, dogs and monkeys. Drug Metab Dispos 11:54-58.
29. Javitt DC, Sershen H, Hashim A and Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202-204.
30. Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
31. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U and Lindenmayer J-P (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
32. Kemp JA, Marshall GR and Priestley T (1991) A comparison of the agonist-dependency of the block produced by uncompetitive NMDA receptor antagonists on rat cortical slices. Mol Neuropharmacol 1:65-70.
33. Kim JS, Kornhuber HH, Schmid-Burgk W and Holzmüller R (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci Lett 20:379-382.
34. Koek W, Woods JH and Winger GD (1988) MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and Rhesus monkeys. J Pharmacol Exp Ther 245:969-974.
35. Korttila K and Levänen J (1978) Untoward effects of ketamine combined with diazepam for supplementing conduction anaesthesia in young and middle-aged adults. Acta Anaesth Scand 22:640-648.
36. Kretschmer BD, Zadow B, Volz TL, Volz L and Schmidt WJ (1992) The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J Neural Transm Gen Sect 87:23-35.
37. Kristensen JD, Svensson B and Gordh T Jr (1992) The NMDA-receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain 51:249-253.
38. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199-214.
39. Kuribara, H, Asami T, Ida I and Tadokoro S (1992) Characteristics of the ambulation-increasing effect of the noncompetitive NMDA antagonist MK-801 in mice: Assessment by the coadministration with central-acting drugs. JPN J Pharmacol 58:11-18.
40. 125]MK-801 binding in the hippocampus of male rats. Brain Res 683:270-274.
41. Larson J, Le T-T, Hall RA and Lynch G (1994) Effects of cyclothiazide on synaptic responses in slices of adult and neonatal rat hippocampus. Neuroreport 5:389-392.
42. Li X, Orwar O, Revesjö C and Sandberg M (1996) Gamma-glutamyl peptides and related amino acids in rat hippocampus in vitro: Effect of depolarization and gamma-glutamyl transpeptidase inhibition. Neurochem Int 29:121-128.
43. Lipa SM and Kavaliers M (1990) Sex differences in the inhibitory effects of the NMDA antagonist, MK-801, on morphine and stress-induced analgesia. Brain Res Bull 24:627-639.
44. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C and Hommer D (1990) Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28:35-40.
45. Lyon M (1991) Animal models with parallels to schizophrenia. Neuromethods 18:25-66.
46. Mansheim P (1989) A case of acute psychosis in temporal association with theophylline toxicity. J Clin Psychopharmacol 9:65-66.
47. 3H]Dizocilpine association kinetics distinguish stimulatory and inhibitory polyamine sites of N-methyl-D-aspartate receptors. J Neurochem 63:963-971.
48. McDonald JW and Johnston MV (1990) Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 15:41-70.
49. Meister A and Tate SS (1976) Glutathione and related γ-glutamyl compounds: Biosynthesis and utilization. Ann Rev Biochem 45:559-604.
50. Moghaddam B (1994) Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Progr Neuro-Psychopharmacol & Biol Psychiatry 18:859-870.
51. Murata S and Kawasaki K (1993) Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor/channel complex. Eur J Pharmacol 239:9-15.
52. Nabeshima T, Yamaguchi K, Furukawa H and Kameyama T (1984) Role of sex hormones in sex-dependent differences in phencyclidine-induced stereotyped behaviors in rats. Eur J Pharmacol 105:197-206.
53. Olney JW and Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
54. Ögren SO and Goldstein M (1994) Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11:167-177.
55. Peacock MD, Schenk DA, Lawrence RA, Morgan JA and Jenkinson SGJ (1994) Elimination of glutathione-induced protection from hyperoxia by acivicin. Appl Physiol 76:1279-1284.
56. Porter RP and Greenamyre JT (1995) Regional variation in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential. J Neurochem 64:614-623.
57. Raffa RB, Ortegón ME, Robisch DM and Martin GE (1989) In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci 44:1593-1599.
58. Rambabu K, Matsuda Y and Katunuma N (1986) Studies on turnover rates of rat γ-glutamyltranspeptidase after chronic ethanol administration in vivo. Biochem Med Metabol Biol 35:335-344.
59. 3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines. J Neurochem 51:830-836.
60. Rosse RB, Colline JP Jr, Fay-McCarthy M, Alim TN, Wyatt RJ and Deutsch SI (1994) Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychosis: A retrospective study. Clin Neuropharmacol 17:359-369.
61. Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG and Deutsch SI (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label, pilot study. Clin Neuropharmacol 12:416-424.
62. Schubert P (1988) Physiological modulation by adenosine: Selective blockade of A1-receptors with DPCPX enhances stimulus train-evoked neuronal Ca influx in rat hippocampal slices. Brain Res 458:162-165.
63. Schwartz PH and Wasterlain CG (1993) Determination of serum and brain concentrations of neuroprotective and non-neuroprotective doses of MK-80. J Neurol Sci 115:26-31.
64. Simeon J, Fink M and Ponce D (1970) D-Cycloserine therapy of psychosis by symptom provocation. Compr Psychiatry 11:80-88.
65. Snyder SH (1980) Phencyclidine. Nature (Lond) 285:355-356.
66. Squires RF and Saedrup E (1991) A review of evidence for GABAergic predominance/ glutamatergic deficit as a common etiologic factor in both schizophrenia and affective psychoses: More support for a continuum hypothesis of "functional" psychosis. Neurochem Res 16:1099-1111.
67. Sturgeon RD, Fessler RG and Meltzer HY (1979) Behavioral ratings for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia. Eur J Pharmacol 59:169-179.
68. Sturgeon RD, Fessler RG, London SF and Meltzer HY (1981) A comparison of the effects of neuroleptics on phencyclidine-induced behaviors in the rat. Eur J Pharmacol 76:37-53.
69. Taylor SA, Crowley J, Pollock TW, Eyre HJ, Jaeckle C, Hynes HE and Stephens RL (1991) Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: A southwest oncology group trial. J Clin Oncol 9:1476-1479.
70. Tiedtke PI, Bischoff C and Schmidt WJ (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm Gen Sect 81:173-182.
71. Toth E and Lajtha A (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11:393-400.
72. Troupin AS, Mendius JR, Cheng F and Risinger MW (1986) MK-801, in New Anticonvulsant Drugs (Meldrum BS and Porter RJ eds) pp 191-201, Libbey, London.
73. Vezzani A, Serafini R, Stasi MA, Caccia I, Tridico RV and Samanin R (1989) Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J Pharmacol Exp Ther 249:278-283.
74. Wagner EJ, Moore KE and Lookingland KJ (1993) Sexual differences in N-methyl-D-aspartate receptor-mediated regulation of tuberoinfundibular dopaminergic neurons in the rat. Brain Res 611:139-146.
75. Watanabe M, Inoue Y, Sakimura K and Mishina M (1993) Distinct distribution of five W-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain. J Comp Neurol 338:377-390.
76. Waziri R (1988) Glycine therapy of schizophrenia. Biol Psychiatry 23:210-211.
77. White BC, Simpson CC, Adams JE and Harkins Jr D (1976) Monoamine synthesis and caffeine-induced locomotor activity. Neuropharmacology 17:511-513.
78. Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN and Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83:7104-7108.